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Abstract
Background: Tumour surveillance via induction of TRAIL-mediated apoptosis is a key mechanism, how the
immune system prevents malignancy. To determine if gene variants in the TRAIL receptor I (DR4) gene affect the
risk of hepatitis C virus (HCV)-induced liver cancer (HCC), we analysed DR4 mutations C626G (rs20575) and A683C
(rs20576) in HCV-infected patients with and without HCC.
Methods: Frequencies of DR4 gene polymorphisms were determined by LightSNiP assays in 159 and 234 HCV-
infected patients with HCC and without HCC, respectively. 359 healthy controls served as reference population.
Results: Distribution of C626G and A683C genotypes were not significantly different between healthy controls and
HCV-positive patients without HCC. DR4 variants 626C and 683A occurred at increased frequencies in patients with
HCC. The risk of HCC was linked to carriage of the 626C allele and the homozygous 683AA genotype, and the
simultaneous presence of the two risk variants was confirmed as independent HCC risk factor by Cox regression
analysis (Odds ratio 1.975, 95% CI 1.205-3.236; p = 0.007). Furthermore HCV viral loads were significantly increased
in patients who simultaneously carried both genetic risk factors (2.69 ± 0.36 × 10
6 IU/ml vs. 1.81 ± 0.23 × 10
6 IU/
ml, p = 0.049).
Conclusions: The increased prevalence of patients with a 626C allele and the homozygous 683AA genotype in
HCV-infected patients with HCC suggests that these genetic variants are a risk factor for HCC in chronic hepatitis C.
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Background
Nearly 3% of the world population, app. 180 million peo-
ple, suffer from hepatitis C virus infection (HCV) thus
representing a global health problem [1]. In most of the
cases exposure to HCV results in chronic viral persistence.
Progression of chronic hepatitis C leads to liver fibrosis
and cirrhosis and is associated with an increased risk to
develop hepatocellular carcinoma (HCC) [2,3]. HCC has
become the third leading cause of cancer-related death
worldwide [4-6], and in Western Countries chronic hepa-
titis accounts for the majority of HCCs. HCV proteins can
interact with tumour suppressor proteins as well as with
proteins involved in cell-cycle control, and these interac-
tions may promote the development of abnormal cells in
the liver.
Tumour development is normally prevented by the
immune system, which eliminates transformed cells via
induction of apoptosis by tumour necrosis factor-related
apoptosis-inducing ligand (TRAIL) [7,8]. Binding of
TRAIL to its cognate death receptors DR4 and DR5
triggers activation of the apoptotic cascade, formation of
apoptotic bodies and eventually to depletion of the
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tumour necrosis factor super family and are character-
ized by the existence of an extra-cellular cysteine-rich
binding domain as well as an intra-cellular death
domain essential for the transmission of the apoptotic
stimulus.
Genetic alterations in death receptors might compro-
mise apoptotic cell signalling and therefore contribute to
the development of tumour cells. Several studies sug-
gested an increased risk for cancer associated with single
nucleotide polymorphisms (SNPs) in the DR4 gene
[9-13]. However, the potential influence of DR4 gene
mutations on the development of HCC has not been
investigated so far. Therefore, we analysed the effect of
the DR4 polymorphisms C626G (Thr209Arg, rs20575)
and A638C (Glu228Ala, rs20576) on the occurrence of
HCC in patients chronically infected with HCV.
Methods
Design and study population
A total of 393 patients with chronic hepatitis C virus gen-
otype 1 infection from the Bonn and Berlin University
Departments of Gastroenterology were enrolled into this
study including 159 patients with HCV-associated HCC
and 234 patients without HCC. In addition 359 HCV-
negative healthy individuals and 56 patients with HCC
caused by chronic hepatitis B served as control groups.
All subjects in this study were of Caucasian descent.
Further clinical and demographic characteristics are
listed in Table 1.
Cirrhosis was diagnosed either by liver biopsy, transient
elastography (stiffness > 15 kPa), and signs of portal
hypertension (splenomegaly, esophageal varices, ascites).
The diagnosis of HCC was made by contrast enhanced
magnetic resonance imaging and computed tomography
according to recently established diagnostic criteria
[EASL 2009 and AASLD 2010 guidelines].
Informed consent was obtained from all patients. The
study conformed to the ethical guidelines of the Helsinki
declaration and had been approved by the University of
Bonn ethics committee (reference number: 019/07).
Diagnosis of HCV Infection
HCV antibodies were detected with a micro particle
enzyme immunoassay (Axsym; Abbott) and confirmed by
dot immunoassay (Matrix; Abbott). HCV RNA was
detected with a nucleic acid purification kit (QIAamp
Viral Kit; Qiagen, Hilden, Germany), followed by reverse
transcription and nested polymerase chain reaction.
Quantitative determination of HCV loads was done by
branched DNA technology (Chiron, Emeryville, CA).
HCV genotype was determined by the Innolipa II line
probe assay (Innogenetics, Zwijndrecht, Belgium).
DR4 Genotyping
Genomic DNA was extracted from 200 μl EDTA-blood
using the QIAamp Blood Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’sp r o t o c o l .
Determination of the DR4 gene polymorphisms C626G
(rs20575) and A683C (rs20576) were performed by Light-
Cycler real time PCR (Roche, Mannheim, Germany) using
commercial LightSNiP (SimpleProbe) assays from TIB-
MolBiol (Berlin, Germany) according to the manufac-
turer’s recommendations.
Statistical analysis
Genotype frequencies were determined and tested for con-
sistency with Hardy-Weinberg equilibrium using an exact
test. Allele and genotype frequencies were compared
between cases and controls by Pearson’s goodness-of-fit
(c
2)t e s ta n dA r m i t a g e ’s trend test, respectively (http://
ihg2.helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl).
Statistical analysis was performed with SPSS 18.0 (SPSS,
Munich, Germany). Data are given as means ± SD, unless
stated otherwise. Differences between groups were ana-
lyzed by t-test and Mann-Whitney-U test as appropriate.
To take into account potentially confounding risk fac-
tors of cirrhosis (age, gender, HBV infection, alcohol
and obesity), univariate comparisons (ANOVA and
chi2-statistics) followed by forward conditional logistic
regression were performed. Parameters with univariate
effects at p < 0.1 were entered into the multivariate ana-
lysis with p < 0.05 for inclusion and p >0 . 1f o re x c l u -
sion as selection criterion for parameters in the final
statistical model.
Results
The distribution of DR4 C626 > G and A683 > C
genetic variants matched the Hardy-Weinberg equili-
brium in all analysed groups and subgroups. HCV-
infected patients without HCC revealed a slightly higher
allele frequency of the DR4 626C allele (47.2%) - corre-
sponding to an increased prevalence of 626C carriers
(70.4%) - than our healthy controls (allele frequency
41.5%; frequency of 626C carriers 65.3%; Figure 1A).
These differences within the HCV-infected patient
groups were apparently independent from the presence
of cirrhosis and did not reach statistically significance.
Prevalence of carriers with a 626C allele (genotypes
626CG and CC) (79.9%) and 626C allele frequency (52.5%)
were significantly increased in the patients with HCV-
associated HCC (Figure 1A). The 626C allele frequency in
patients with HCV-associated HCC was significantly dif-
ferent only from that in healthy controls (OR = 1.556, 95%
CI: 1.192-2.031, p = 0.001).
Importantly, the increased prevalence of carriers with a
626C allele reached statistical significance both with
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3.290, p = 0.001) and to HCV-infected patients without
HCC (OR = 1.670, 95% CI: 1.034-2.696, p =0 . 0 3 4 )
(Figure 1A).
The distribution of A683 > C variants did not differ
between healthy controls and HCV-infected patients
without HCC irrespective from the presence of cirrhosis
(Table 1). Patients with HCV-associated HCC had the
highest frequency of the 623A allele (86.5%), which was
significantly increased as compared to healthy controls
(A allele frequency 77.3%, OR = 1.856 95% CI: 1.291-
2.667, p = 0.0006) and HCV-infected patients without
HCC (A allele frequency 77.6%, OR = 1.828, 95% CI:
1.243-2.686, p = 0.002). This deviation was strong enough
to achieve statistical significance even when HCV-
infected subgroups with and without cirrhosis were com-
pared separately (cirrhosis: 77.3% A allele frequency,
OR = 1.852, 95% CI: 1.126-3.045, p = 0.013; without cir-
rhosis: 77.7% A allele frequency, OR = 1.816, 95% CI:
1.201-2.746, p = 0.004).
These changes were due to a significant increase in the
proportion of patients with the homozygous 683AA gen-
otype in patients with HCV associated HCC (76.1%) as
compared to healthy controls (59.9%, OR = 0.477, 95%
CI: 0.314-0.725, p = 0.0003) and HCV-infected patients
without HCC (59.4%, OR = 0.468, 95% CI: 0.300-0.730,
p = 0.0006), irrespective whether cirrhosis was present
(60.0%, OR = 0.480, 95% CI: 0.267-0.862, p = 0.011) or
not (59.1%, OR = 0.462, 95% CI: 0.286-0.747, p =0 . 0 0 1 )
(Figure 1B). Interestingly, HCV viral loads tended to be
increased in patients who carried the genetic risk variants
associated with polymorphisms C626G (2.44 ± 0.28 × 10
6
IU/ml vs. 1.85 ± 0.30 × 10
6 IU/ml, n.s.) and A683C (2.30 ±
0.27 × 10
6 IU/ml vs. 1.94 ± 0.26 × 10
6 IU/ml, n.s.), and
this effect reached statistical significance in patients who
simultaneously carried both genetic risk factors (2.69 ±
0.36 × 10
6 IU/ml vs. 1.81 ± 0.23 × 10
6 IU/ml, p = 0.049)
(Figure 2).
Next, we checked whether variants in the TRAIL
receptor I (DR4) gene were confirmed as independent
HCC risk factors in HCV-infected patients when known
risk factors such as age, sex, obesity, diabetes, HCV viral
load and HBV co-infection were also taken into account
(Table 2). Univariate analysis identified age (OR = 1.076
per year, 95% CI: 1.053-1.098, p < 0.0001), carriage of a
626C allele (OR = 1.670, 95% CI: 1.034-2.696, p =0 . 0 3 5 ) ,
the homozygous 683AA genotype (OR = 2.176, 95% CI:
1.390-3.407, p = 0.001) and the simultaneous presence of
both genetic variants (OR = 1.940, 95% CI: 1.280-2.940,
p = 0.002) as risk factors of HCC (Table 2). In the multi-
variate regression analysis age was found to be an inde-
pendent risk factor for the development of HCC in
chronic hepatitis C (OR = 1.074, 95% CI: 1.052-1.097, p ≤
0.001). More importantly, we could confirm that the
simultaneous presence of a 626C allele in combination
with the homozygous 683AA genotype was significantly
Table 1 Patient characteristics and distribution of DR4 genotypes
Healthy
controls
HCV(+) all
without HCC
HCV(+) Cirrhosis (-)
Without HCC
HCV(+) Cirrhosis (+)
without HCC
HCV(+) Cirrhosis
(+) with HCC
HBV(+)
With HCC
Numbers 359 234 159 75 159 56
Median age (range) 59 (35-69) 52 (39-63) 46 (39-57) 55 (49-63) 62 (54-70) 60(24-83)
Male Gender (%) 51.4 66.2 65.2 69.7 58.6 75.0
HCV infection (%) - 100 100 100 100 0
HCV genotype 1 (%) - 100 100 100 100 -
HCV viral load(10
6 IU/ml)
a) - 2.04 ± 0.25 2.10 ± 0.29 1.86 ± 0.48 1.88 ± 0.36 -
HBV infection (%) - 3.2 2.8 4.0 4.4 100
BMI > 30 (%) - 17.1 15.0 21.7 26.2 21.4
Diabetes (%) - 7.7 0.8 23.0 12.0 3.6
rs20575 (C626G)
b) 349 (100) 233 (100) 159 (100) 74 (100) 159 (100) 56 (100)
CC 62 (17.8) 56 (24.0) 38 (23.9) 18 (24.3) 40 (25.2) 9 (16.1)
CG 166 (47.6) 108 (46.4) 74 (46.5) 34 (45.9) 87 (54.7) 30 (53.6)
GG 121 (34.7) 69 (29.6) 47 (29.6) 22 (29.7) 32 (20.1) 17 (30.4)
Deviation from Hardy-
Weinberg equilibrium
c)
p = 0.74 p = 0.29 p = 0.43 p = 0.49 p = 0.27 p = 0.59
rs20576 (A683C)
b) 359 (100) 234 (100) 159 (100) 75 (100) 159 (100) 56 (100)
CC 19 (5.3) 10 (4.3) 6 (3.8) 4 (5.3) 5 (3.1) 1 (1.8)
AC 125 (34.8) 85 (36.3) 59 (35.0) 26 (34.7) 33 (21.9) 17 (30.4)
AA 215 (59.9) 139 (59.4) 94 (59.1) 45 (60.0) 121 (75.8) 38 (67.9)
Deviation from Hardy-
Weinberg equilibrium
c)
p = 0.88 p = 0.58 p = 0.49 p = 1.0 p = 0.17 p = 1.0
a) Mean ± SEM,
b) Number of patients (number/% of total),
c) Fisher’s exact test
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Figure 1 Frequencies of DR4 risk alleles in HCV-infected patients with and without HCC. Figure A shows the frequency of carriers with a
DR4 626 C risk allele, and figure B the frequency of patients with the homozygous DR4 683AA genotype. Figure C shows the frequency of
patients who carried either the 626CG or 626CC risk genotype in combination with the homozygous DR4 683AA genotype. Differences between
the various patient groups were analyzed by chi
2 statistics.
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Page 4 of 7associated with the occurrence of HCC in this continua-
tive analysis (OR = 1.975, 95% CI: 1.205-3.236, p = 0.007)
and could therefore identify the combined carriage of a
DR4 risk variant as new independent predictor for the
development of HCC in chronic hepatitis C.
To check, if our findings were specific for hepatitis C,
we performed a similar analysis in our group of HCC
patients, who had chronic hepatitis B. However, unlike
hepatitis C-associated HCC the distributions of genetic
DR4 variants in HBV-associated HCC, healthy controls
and HCV-positive patients without HCC were not sig-
nificantly different (Table 1). In particular, the simulta-
neous combination of a 626C allele with the 683AA
genotype was observed in rather similar frequencies in
the groups with HBV-associated HCC (50.0%), hepatitis
C without HCC (49.4%) and healthy controls (47.0%)
while the difference in frequency between HBV-and
HCV-associated HCC (65.4%) was significant (OR =
1.891, 95% CI: 1.020-3.506, p = 0.042).
Discussion
Emerging evidence suggest an important role of TRAIL
for control and elimination of HCV infection. TRAIL has
been implicated in the death of HCV-infected but not nor-
mal liver cells [14]. In HCV infection its expression on
natural killer cells is up-regulated by interferon, and is
inversely correlated to HCV-RNA serum levels [15,16].
TRAIL can also induce cell death in hepatic tumour cells
but expression of TRAIL receptors on human hepatocellu-
lar carcinoma is variable and frequently down-regulated
[17]. Nevertheless, several studies suggest TRAIL recep-
tor-mediated apoptosis to play a role in the elimination of
tumour cells in human hepatocellular carcinoma [18,19].
In this study we found that the TRAIL receptor I wild
type with threonine at amino acid position 209 (626C)
and alanine at position 228 (638A) is associated with an
i n c r e a s e dr i s ko fH C Ci np a t i ents with chronic hepatitis
C. Of note, it was particularly the combination of the risk
genotypes 626CC or 626CG with the homozygous
683AA genotype that was identified as a new indepen-
dent predictor for HCC. Interestingly, this association of
DR4 genetic variants and the risk to develop HCC was
evident only for patients with chronic hepatitis C but not
hepatitis B, suggesting a critical role of the aetiology
underlying HCC. Both polymorphisms in the DR4 gene
have already been reported to affect the risk for other
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Figure 2 HCV viral loads in patients with and without genetic
DR4 risk variants. This Figure shows HCV viral loads (Means ±
SEM) in patients who carry the DR4 626CG or 626CC risk variant (left
columns), the DR4 683AA risk variant (middle columns) and both
DR4 risk variants simultaneously (right columns). Dark columns refer
to patients with the studied risk factor, grey columns to those
without the risk factor, respectively. Differences were compared by
ANOVA.
Table 2 Regression analysis for risk factors of HCC among patients with hepatitis C genotype 1
Univariate analysis
95% Confidence interval
Parameter p-value Odds ratio Lower Upper
Age
§ 0.000 1.076 1.053 1.098
Diabetes mellitus 0.369 1.412 0.691 2.886
Gender (male) 0.135 1.430 0.915 2.236
HBV infection 0.626 1.295 0.460 3.646
HCV viral load (10
6 IU/ml) 0.339 0.960 0.883 1.044
Obesity (BMI > 30) 0.153 1.668 0.867 3.211
C626G genotype ([CC+CG] vs. GG) 0.035 1.670 1.034 2.696
A683C genotype (AA vs. [AC+CC]) 0.001 2.176 1.390 3.407
Combined 626C and 683AA risk genotype vs. all other combinations 0.002 1.940 1.280 2.940
Multivariate analysis*
95% Confidence interval
Parameter p-value Odds ratio Lower Upper
Age
§ 0.000 1.074 1.052 1.097
Combined 626C and 683AA risk genotype 0.007 1.975 1.205 3.236
* including all significant parameters from univariate analysis,
§ OR (95% CI) per year
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tigating the role of the DR4 A683C polymorphism in
chronic lymphocytic leukaemia, mantle cell lymphoma,
prostate cancer, head and neck squamous cell carcinoma
and bladder cancer an increased frequency of the CC
genotype was apparently linked to malignancy [20]. In
contrast, Frank et al. observed an increased percentage of
carriers with the AA genotype in patients with breast
cancer [10]. Moreover, they found an increased percen-
tage of carriers of the 626CC genotype similar to our
results. At present, it remains unclear which mechanisms
underlie DR4 polymorphisms C626G and A683C to
affect the risk for malignancy.
However, both amino acid exchanges are in the extra-
cellular cysteine-rich domain of DR4. Therefore both
genetic variants may lead to alterations in the TRAIL-
binding domain and thus alter DR4 affinity for TRAIL.
Since TRAIL signalling presumably contributes impor-
tantly to the control of HCV infection, our finding of sig-
nificantly increased HCV viral loads in carriers of both
DR4 risk factors suggests that TRAIL-DR4 signalling is
less efficient in these patients. In line with this reasoning
less efficient signalling of cell death in transformed cells
and reduced susceptibility of transformed hepatocytes
towards TRAIL-induced apoptosis would also facilitate
HCC development. On the other hand, we cannot
exclude the possibility that the increased HCC risk in
HCV-infected patients carrying the C626G and A683C
risk variants of TRAIL receptor I simply reflects less effi-
cient immune control over HCV infection via TRAIL-
mediated mechanisms. TRAIL is likely to affect tumour
surveillance of transformed HCV-infected cells by the
immune system and viral loads, once HCV infection has
occurred [14]. On the other hand our data suggest that
neither of the DR4 polymorphisms affects susceptibility
to HCV infection. This constellation can be explained by
the fact that DR4 expression is rather low on normal
liver cells while up-regulated DR4 expression following
HCV infection sensitizes liver cells towards TRAIL-
mediated apoptosis [14,21]. Thus, sufficient DR4 expres-
sion on transformed liver cells appears to be a pivotal
prerequisite for efficient tumour surveillance by the
immune system, in line with recent clinical findings [17].
Therefore the role of TRAIL and DR4 polymorphisms
should be further studied in patients whose risk for
HCC is attributed to different aetiologies.
Conclusion
Here, we provide first evidence that HCV genotype 1
infected carriers of a DR4 626C allele in combination
with the DR4 683AA genotype have an increased risk for
HCC indicating that TRAIL and its receptors contribute
importantly to control of HCV infection and tumour sur-
veillance by the immune system. The combined presence
of the two DR4 risk variants can help to identify HCV-
infected patients with an increased risk for liver cancer,
who may need more intensive cancer monitoring.
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